Population-based study of breast cancer survival in Cote d'Or (France): Prognostic factors and relative survival

Annals of Oncology

Volumn 19, Issue 2, 2008, Pages 276-283

  Dabakuyo, T S ^a,e   Bonnetain, F ^a,e   Roignot, P ^b   Poillot, M L ^b   Chaplain, G ^a   Altwegg, T ^c   Hedelin, G ^d   Arveux, P ^a,e  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b Centre de Pathologie   (France)

^c Centre Radiotherapie Du Parc   (United Kingdom)

^d Faculty of Medicine   (United Kingdom)

^e UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Breast cancer; Crude survival; Epidemiology; Population based cancer registry; Prognostic factors; Relative survival

Indexed keywords

PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; FRANCE; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CANCER; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CAUSE OF DEATH; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FRANCE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 38849126732     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm491     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-488.
3. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-1727.
4. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal replacement therapy: Collaborative reanalysis of individual data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047-1059.
5. Chia KS, Du WB, Sankaranarayanan R et al. Population-based cancer survival in Singapore. 1968 to 1992: An overview. Int J Cancer 2001; 93: 142-147.
6. Kuru B. Prognostic significance of total number of nodes removed, negative nodes removed, and ratio of positive nodes to removed nodes in node positive breast carcinoma. Eur J Surg Oncol 2006; 32: 1082-1088.
7. Kim KJ, Huh SJ, Yang JH et al. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy. Jpn J Clin Oncol 2005; 35: 126-133.
8. Westenend PJ, Meurs CJC, Damhuis RAM. Tumour size and vascular invasion predict distant metastasis in stage I breast cancer. Grade distinguishes early and late metastasis. J Clin Pathol 2005; 58: 196-201.
9. Mirza AN, Mirza NQ, Vlastos G, Singletary SE. Prognostic factors in node negative breast cancer. A review of studies with sample size more than 200 and follow up more than 5 years. Ann Surg 2002; 235: 10-26.
10. Schaapveld M, De Vries EGE, Van der Graaf WTA et al. The prognostic effect of the number of histologically examined axillary lymph nodes in breast cancer: Stage migration or age association? Ann Surg Oncol 2006; 13: 465-474.
11. Ederer F, Heise H. The Effect of Eliminating Deaths from Cancer in General Population Survival Rates. Technical Report, National Cancer Institute 1959. Methodological Note 11 End Results Evaluation Section.
12. Sobin LH, Wittekind C (eds): International Union Against Cancer (UICC): TNM Classification of Malignant Tumors, 5th edition, New York, NY: Wiley-Liss 1997.
13. Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med 2004; 24: 51-64.
14. Black RJ, Sankarananarayanan R, Parkin DM. Interpretation of population-based cancer survival data. In: Sankaranarayanan R, Black RJ, Parkin DM (eds): Cancer Survival in Developing Countries. IARC Scientific Publication No. 145. Lyon, France: International Agency for Research on Cancer 1998.
15. Sant M, Aareleid T, Berrino F et al. EUROCARE-3: Survival of cancer patients diagnosed 1990-94 - results and commentary. Ann Oncol 2003; 14: 61-118.
16. Remontet L, Estève J, Bouvier A-M et al. Cancer incidence and mortality in France over the period 1978-2600. Rev Epidemiol Sante Publique 2003; 51: 3-30.
17. Sant M and the Eurocare Working Group. Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer 2003; 106: 416-422.
18. Sant M, Allemani C, Berrino F et al. Breast carcinoma survival in Europe and the United States. Cancer 2004; 100: 715-722.
19. Holli K, Isola B. Effect of age on the survival of breast cancer patients. Eur J Cancer 1997; 33: 425-428.
20. Brenner H, Hakulinen T. Are patients diagnosed with breast cancer before age 50 years ever cured? J Clin Oncol 2004; 22: 432-438.
21. Sant M and the Eurocare Working Group. Differences in stage and therapy for breast cancer across Europe. Int J Cancer 2001; 93: 894-901.
22. Nsb HW, Hop WC, Crommelin MA et al. Improved prognosis of breast cancer since 1970 in south-eastern Netherlands. Br J Cancer 1994; 70: 285-288.
23. Osbome CK, Yochmowitz MG, Knight WA III, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980; 46: 2884-2888.
24. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998; 351: 1451-1467.
25. Adjuvant Therapy for Breast Cancer. NIH consensus statement Volume 17, Number 4. November 1-3, 2000. [on-line] 2000; http://odp.od.nih.,gov/ consensus (11 October 2007, date last accessed).
26. Camp RL, Rimm EB, Rimm DL. A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome. Cancer 2000; 88: 108-113.
27. Moorman PG, Hamza A, Marks JR, Olson JA. Prognostic significance of the number of lymph nodes examined in patients with lymph node-negative breast carcinoma. Cancer 2001; 91: 2258-2262.
28. Krag DN, Single RM. Breast cancer survival according to number of nodes removed. Ann Surg Oncol 2003; 10: 1152-1159.
29. Polednak AP. Survival of lymph node-negative cancer in relation to number of lymph nodes examined. Ann Surg 2003; 237: 163-167.
30. Weir L, Speers C, D'yachkova Y, Olivotto IA. Prognostic significance of the number of axillary lymph nodes removed in patients with node-negative breast cancer. J Clin Oncol 2002; 20: 1793-1799.